Stock Comparison

JAZZ vs JNJ

Jazz Pharmaceuticals PLC vs Johnson & Johnson

The Verdict

JNJ takes this one.

JAZZ

Jazz Pharmaceuticals PLC

0.7

out of 10

Distressed

Winner

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$11.9B

Market Cap

N/A

-33.3

P/E Ratio

N/A

-8.3%

Profit Margin

N/A

-8.8%

Return on Equity

N/A

1.2

Debt-to-Equity

N/A

Moderate

Overall Risk

Conservative

0.7

DVR Score

1.0

The Deep Dive

JAZZ0.7/10

Jazz Pharmaceuticals remains a well-established biopharmaceutical company with strong execution on its neuroscience and oncology portfolio. The Q4 2025 earnings beat, 10% YoY revenue growth, and 16% YoY Xywav revenue growth demonstrate stable performance. The advancement of zanidatamab (HER2+ GEA) with breakthrough designation and potential H2 2026 approval provides a significant near-term catalys...

Full JAZZ Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.